NCT02103335 - Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2014

Primary Completion Date

October 3, 2016

Study Completion Date

November 30, 2016

Conditions

Multiple Myeloma in RelapseRefractory Multiple MyelomaMultiple Myeloma

Interventions

DRUG

pomalidomide

Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg

DRUG

marizomib

IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle

DRUG

low-dose dexamethasone

Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg

Trial Locations (6)

Peter MacCallum Cancer Centre, East Melbourne

Alfred Hospital, Prahran

University of Maryland, Baltimore

Karmanos Cancer Center, Detroit

University of Chicago Medical Center, Chicago

Dana Farber Cancer Institute, Boston